Description: Predictive Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: AIPT until June 12, 2019; POAI starting June 13, 2019) operates through its three business units, Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Home Page: www.predictive-oncology.com
POAI Technical Analysis
2915 Commers Drive
Eagan,
MN
55121
United States
Phone:
651 389 4800
Officers
Name | Title |
---|---|
Mr. Raymond F. Vennare | CEO & Chairman |
Mr. Robert L. Myers M.B.A. | CFO & Sec. |
Mr. Richard L. Gabriel B.S., B.Sc, M.B.A., MBA | Sr. VP of R&D |
Dr. Julia Kirshner Ph.D. | Chief Scientific Officer |
Ms. Theresa Ferguson | Sr. Director of Marketing |
Ms. Pamela Bush M.B.A., Ph.D. | Sr. VP of Strategic Sales & Bus. Devel. |
Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. | Sr. VP of Protein Science |
Dr. Arlette H. Uihlein FCAP, M.D. | Sr. VP of Drug Discovery Operations & Medical Director |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.0917 |
Price-to-Sales TTM: | 19.5901 |
IPO Date: | 2018-01-29 |
Fiscal Year End: | December |
Full Time Employees: | 30 |